Table 1.
Demographics and baseline characteristics (ITT population)
| Variable | Netarsudil 0.02% QD N = 122 |
Ripasudil 0.4% BID N = 123 |
All subjects N = 245 |
p valuea |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 44 (36.1) | 57 (46.3) | 101 (41.2) | 0.1197 |
| Female | 78 (63.9) | 66 (53.7) | 144 (58.8) | |
| Age (years) | ||||
| Mean (SD) | 61.4 (13.18) | 62.0 (12.99) | 61.7 (13.06) | 0.7318 |
| Age Category, n (%) | ||||
| < 65 years | 63 (51.6) | 60 (48.8) | 123 (50.2) | 0.7021 |
| > = 65 years | 59 (48.4) | 63 (51.2) | 122 (49.8) | |
| Study eye diagnosis, n (%) | ||||
| Ocular hypertension | 32 (26.2) | 35 (28.5) | 67 (27.3) | 0.7747 |
| Primary open angle glaucoma | 90 (73.8) | 88 (71.5) | 178 (72.7) | |
| Prior prostaglandin therapy, n (%) | ||||
| No prostaglandin therapy | 48 (39.3) | 57 (46.3) | 105 (42.9) | 0.3024 |
| Prostaglandin therapy | 74 (60.7) | 66 (53.7) | 140 (57.1) | |
| Mean diurnal IOP (mmHg) at day 1 (baseline)—study eye | ||||
| Mean (SD) | 20.48 (2.77) | 20.83 (3.55) | 20.65 (3.18) | 0.3840 |
BID twice daily, IOP intraocular pressure, ITT intent-to-treat, N number of patients in the given treatment of ITT population, n number of patients in a given category, QD once daily, SD standard deviation
ap values are from tests of differences between treatment groups and are 2-sided. Fisher’s exact test was used for categorical variables and one-way analysis of variance was used for continuous variables